Skip to content

Impact of Training Status on Bioavailability of Flavanones

Impact of Training Status of Endurance Athletes on Bioavailability of Flavanones

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02627547
Enrollment
13
Registered
2015-12-11
Start date
2013-09-30
Completion date
2015-08-31
Last updated
2015-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Flavanones, Endurance-trained athletes, Biological availability

Brief summary

Flavonoids are compounds that have been proven to have a beneficial effect on health, such as reducing the risk of developing cardiovascular disease and, in some cases, cancer. Citrus juices have a high flavonoid content. However, the absorption of flavonoids into the body is limited. This study will investigate whether being physically active improves the absorption of flavonoids. Endurance trained athletes will be invited to participate. Following screening procedures (a. Health Screening Questionnaire; b. height and weight measurement for calculation of Body Mass Index; c. maximal oxygen consumption (VO2max) uptake test, eligible participants will undertake two experimental tests; one during a period of normal training, the other immediately following 1 week of detraining. In the morning of the experimental trial participants will consume 500 mL of orange juice. Blood samples and urinary fractions will be collected prior (base line) to and for 24 hours after orange juice consumption. Participants will be asked to follow a special polyphenol-free diet and record weighed dietary intake for 2 days preceding each trial and during the day of the experimental trial. The study aims to: 1. Determine the effects of training status of endurance athletes on bioavailability of flavanones in endurance trained individuals 2. Determine whether changes in bioavailability of flavanones are related to changes in biomarkers of inflammation, oxidative stress, plasma lipids and insulin sensitivity.

Interventions

BEHAVIORALNormal training

5-10 hours of endurance training each week

BEHAVIORALDe-training

No training

Sponsors

University of Glasgow
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* trained regularly for at least 4 years and typically perform at least 5 hours of endurance training per week (distance runners, triathletes, cyclists) * healthy * normotensive * non-smokers * not taking any drug therapies * VO2 max \>50 ml/kg body mass

Exclusion criteria

* history of gastrointestinal disease * vegetarian * unstable food habits * VO2 max \< 50 ml/kg body mass

Design outcomes

Primary

MeasureTime frameDescription
• Plasma pharmacokinetics of naringenin, hesperetin, eriodictyol, isorhamnetin and phenolic acid metabolites24 hoursChange in plasma concentrations collected at base line (0 hours) and 0.5,1, 2, 3,4,5,6,7,8, and 24 hours after ingestion of orange juice
• Urinary excretion of naringenin, hesperetin, eriodictyol, isorhamnetin and phenolic acid metabolites24 hoursChange in concentrations in urinary fraction collected at base line (0 hours) and after ingestion of orange juice (0-5, 5-8, 8-10, 10-24 hours)

Secondary

MeasureTime frameDescription
Maximal Oxygen Consumption30 minutesMaximal Oxygen Consumption (ml/kg/min) measured in trained state by Douglas bag method
Body weight7 daysDifference in body weight in kilograms between trained and detrained states measured by TANITA scales (TBF-300, Cranlea, UK)
Body fatness7 daysDifference in percentage of body fat between trained and detrained states measured by bioelectrical impedance method (TBF-300, TANITA, Cranlea, UK)
Dietary Intake7 daysDifference in energy/macronutrient intake between trained and detrained states measured from 7 day weighted food records

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026